Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Closes on $3M Registered Direct Offering By: Investor Brand Network April 10, 2023 at 10:12 AM EDT AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, has announced the closing of its previously announced registered direct offering. The offering, a securities purchase agreement with institutional investors, was for $3 million of its American Depositary Shares (“ADSs”), prefunded warrants to purchase ADSs and warrants to purchase ADSs. According to the announcement, the company anticipates using the net proceeds from the offering for its R&D development activities as well as for working capital and general corporate purposes. To view the full press release, visit https://ibn.fm/tQyZt About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. The company intends to enter the business-to-business e-commerce food business with the formation of its wholly owned subsidiary Fresh2 Technology and the acquisition of Fresh2 Ecommerce Inc. For more information about the company, visit www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Closes on $3M Registered Direct Offering By: Investor Brand Network April 10, 2023 at 10:12 AM EDT AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, has announced the closing of its previously announced registered direct offering. The offering, a securities purchase agreement with institutional investors, was for $3 million of its American Depositary Shares (“ADSs”), prefunded warrants to purchase ADSs and warrants to purchase ADSs. According to the announcement, the company anticipates using the net proceeds from the offering for its R&D development activities as well as for working capital and general corporate purposes. To view the full press release, visit https://ibn.fm/tQyZt About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. The company intends to enter the business-to-business e-commerce food business with the formation of its wholly owned subsidiary Fresh2 Technology and the acquisition of Fresh2 Ecommerce Inc. For more information about the company, visit www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork
AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, has announced the closing of its previously announced registered direct offering. The offering, a securities purchase agreement with institutional investors, was for $3 million of its American Depositary Shares (“ADSs”), prefunded warrants to purchase ADSs and warrants to purchase ADSs. According to the announcement, the company anticipates using the net proceeds from the offering for its R&D development activities as well as for working capital and general corporate purposes. To view the full press release, visit https://ibn.fm/tQyZt About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. The company intends to enter the business-to-business e-commerce food business with the formation of its wholly owned subsidiary Fresh2 Technology and the acquisition of Fresh2 Ecommerce Inc. For more information about the company, visit www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork